Vivos (RDGL) Net Income towards Common Stockholders (2010 - 2025)
Vivos (RDGL) posted Net Income towards Common Stockholders of -$1.1 million for Q4 2025, down 112.6% sequentially from -$507294.0 in Q3 2025, and down 5.41% YoY from -$1.1 million in Q4 2024.
Vivos (RDGL) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Vivos has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$1.1 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 5.41% year-over-year to -$1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.1 million (down 5.35% YoY) and the FY2025 annual result came in at -$3.1 million, down 5.35% from the prior year.
- Net Income towards Common Stockholders declined to -$1.1 million in Q4 2025 per RDGL's latest filing, from -$507294.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$178230.0 in Q4 2021 and troughed at -$1.9 million in Q2 2021.
- A 5-year average of -$693457.2 and a median of -$683797.5 in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2021 and 2023: Net Income towards Common Stockholders tumbled 1069.29% in 2021, then soared 64.52% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at -$178230.0 in 2021, then tumbled by 295.92% to -$705653.0 in 2022, then sank by 52.51% to -$1.1 million in 2023, then rose by 4.93% to -$1.0 million in 2024, then slipped by 5.41% to -$1.1 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.1 million, -$507294.0, and -$645513.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Vivos | 24.90 Mn | 23.34 Mn | -3,105.00 | -1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | -507,294.00 |
| Jun 30, 2025 | -645,513.00 |
| Mar 31, 2025 | -834,696.00 |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -825,263.00 |
| Jun 30, 2024 | -503,458.00 |
| Mar 31, 2024 | -558,539.00 |
| Dec 31, 2023 | -1.08 Mn |
| Sep 30, 2023 | -667,690.00 |
| Jun 30, 2023 | -902,526.00 |
| Mar 31, 2023 | -248,318.00 |
| Dec 31, 2022 | -705,653.00 |
| Sep 30, 2022 | -277,065.00 |
| Jun 30, 2022 | -787,538.00 |
| Mar 31, 2022 | -699,905.00 |
| Dec 31, 2021 | -178,230.00 |
| Sep 30, 2021 | -201,160.00 |
| Jun 30, 2021 | -1.86 Mn |
| Mar 31, 2021 | -288,189.00 |